TPCW
TGTX icon

TD Private Client Wealth’s TG Therapeutics TGTX Stock Holding History

TD Private Client Wealth’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14
Closed -$543 – 1243
2021
Q2 		$543 Buy
+14
New +$550 ﹤0.01% 1171

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Private Client Wealth's TGTX Position: Q3 2021 in Review

TD Private Client Wealth sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 14 shares — an estimated $543 sold.

TD Private Client Wealth first reported a position in TGTX in Q2 2021 and held it in 1 quarter. The position peaked at $543 in Q2 2021. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

  • TD Private Client Wealth reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
  • TD Private Client Wealth sold 14 TG Therapeutics shares in Q3 2021, an estimated $543.
  • TD Private Client Wealth first reported a position in TG Therapeutics in Q2 2021 and held it in 1 quarter.
  • TD Private Client Wealth's TG Therapeutics position peaked at $543 in Q2 2021.
  • 222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on TD Private Client Wealth's 13F filing for Q3 2021, filed 16 Aug 2024.